The Sanofi Espoir Foundation has a Board of Directors. It meets at least twice a year to set the organization’s broad guidelines, validate strategic projects valued at above 200,000 euros a year.
- 7 founding members
- 2 members of staff
- 4 external experts
Born in 1951, Serge Weinberg has a law degree, graduated from the Institute of Political Studies and is a former student at ENA (1976).
After various assignments as a sub-prefect from 1976 to 1981, he became chief of staff for Laurent Fabius, the Minister for the Budget In 1981.
After being Deputy Director General (Finance) of FR3 (1982-1983), he was appointed CEO and Chairman of Havas Tourism from 1983 to 1987.
After three years as CEO of Pallas Finance, he joined the Pinault Group in 1990 as President of the CFAO. He was then Chairman and CEO of Rexel from 1991 to 1995 and chaired the board of PPR for ten years. In March 2005, he founded Weinberg Capital Partners, an investment company that manages a fund specializing in LBOs and in real estate.
Since May 17, 2010 he has been Chairman of the Board of Directors of Sanofi. Serge Weinberg was also been non-executive Chairman of the Board of Accor from 2006 to 2009.
He is a member of the Attali Commission to spur growth in France from 2007 to 2008 and in 2010.
He is a member of the board of Schneider Electric, the AFEP (French Association of Private Enterprises) and is also a founding member and treasurer of the French Brain and Spinal Cord Institute (ICM).
Paul Hudson joined Sanofi as CEO on September 1, 2019. Previously CEO of Novartis Pharmaceuticals (2016-2019), where he was a member of the Executive Committee, Paul has an expansive international career in healthcare that spans the U.S., Japan and Europe.
Prior to Novartis, he worked for AstraZeneca, where he held several increasingly senior positions and most recently carried out the roles of president, AstraZeneca United States and executive vice president, North America. He began his career in sales and marketing roles at GlaxoSmithKline UK and Sanofi-Synthélabo U.K. Paul holds a degree in economics from Manchester Metropolitan University in the U.K. and last year his alma mater awarded him an honorary Doctor of Business Administration for his achievements in industry. He also holds a diploma in marketing from the Chartered Institute of Marketing, also in the U.K.
“People are what drive me. I was drawn to healthcare so that I could positively impact people’s lives. As a leader, I firmly believe that making an impact starts within–how we do things, how we work with integrity, and how we empower and inspire each other to bring our best selves to work. Even on a tough day, I can be confident that our work has a positive impact on people–either by improving a patient’s life or by inspiring a colleague.” - Paul Hudson
A father of three, Paul, 51, is a hands-on dad and an ardent Manchester United football fan.
Olivier Charmeil is a graduate of HEC (Ecole des Hautes Etudes Commerciales) and of the Institut d’Etudes Politiques in Paris.
From 1989 to 1994, he worked in the Mergers & Acquisitions department of Banque de l’Union Européenne. He joined Sanofi Pharma in 1994 as head of Business Development. Subsequently, he held various positions within Sanofi, including Chief Financial Officer (Asia) of Sanofi-Synthélabo in 1999 and Attaché to the Chairman, Jean-François Dehecq, in 2000, before being appointed as Vice President, Development within the Sanofi-Synthélabo International Operations Directorate, where he was responsible for China and support functions.
In 2003, Olivier Charmeil was appointed Chairman and Chief Executive Officer of Sanofi-Synthélabo France, before taking the position of Senior Vice President, Business Management and Support within the Pharmaceutical Operations Directorate. In this role, he piloted the operational integration of Sanofi-Synthélabo and Aventis. He was appointed Senior Vice President Asia/Pacific, Pharmaceutical Operations in February 2006; Operations Japan reported to him from January 1, 2008, as did Asia/Pacific and Japan Vaccines from February 2009.
On January 1, 2011, Olivier Charmeil was appointed Executive Vice President Vaccines, and joined our Executive Committee. In May 2015, Olivier Charmeil and André Syrota were appointed as Co-Leaders of “Medicine of the Future”, an initiative developed by the French Minister for Economy, Industry and Digital Affairs, the French Minister for Social Affairs, Health and Women’s Rights and the French Minister for National and Higher Education and Research. They have been tasked with assembling a group of industrialists and academics, with the objective of imagining how French industry can accelerate the launch and export of innovative industrial products, with an emphasis on new biotechnologies.
From June 2016 to December 2018, Olivier Charmeil served as Executive Vice President of our General Medicines and Emerging Markets Global Business Unit.
From January 2019 to February 2020, he served as Executive Vice President, China and Emerging Markets. He took up his current position of Executive Vice President, General Medicines in March 2020.
After earning a Doctorate of Pharmacy in the University of Montpellier, France, in 1989, Valérie joined the French affiliate of what is now Sanofi, where she held positions of increasing responsibilities in Regulatory Affairs.
After 15 years of experience in the field of European regulatory affairs, she joined the Access to Medicines department, in the Corporate Social Responsibility Division of Sanofi.
During more than 10 years, Valerie has developed a recognized expertise and network in the area of access to healthcare and quality of medicines in developing countries. In 2017, Valérie Faillat has been appointed Head of the Sanofi Espoir Foundation.
Valérie is a member of the Scientific Advisory Committee of DNDi (Drug for Neglected Diseases Initiative), a collaborative, patients’ needs-driven, non-profit drug research and development organization that is developing new treatments for neglected diseases, and member of the Board of Directors of Tulipe, a not-for-profit organization that federate donations made by pharmaceutical companies to provide an emergency response to the needs of populations in distress as a result of acute health crises, natural disasters or conflicts.
He started working in the European Commission as consultant within the External Affairs Directorate General.
After that he was in charge of the Communication department for the Council of European Municipalities and Regions (CEMR) and, finally he worked at the Cabinet of the President of the EU Committee of the Regions (Pasqual Maragall 1996 - 1998).
In 1998 he went back to Spain as the Director of Communication at Forum de las Culturas Barcelona-2004.
In 2001 he joined Weber Shandwick, the world’s leading PR agency, where he served as CEO for Weber Shandwick Brussels – chairing its European Public Affairs Practice, and afterwards as CEO for Weber Shandwick Spain & Portugal until mid-2010. He then joined Sanofi as Director of Corporate Relations and Communication for Spain and Portugal.
In March 2014 he was appointed VP Communication for Europe, coordinating the communication and patient advocacy strategies for the European Region.
In 2015, He serves as Global Head of Public Affairs and in January 2018, has been appointed Head of Global Communications for the Company.
In February 2020, he has been promoted to Head of Corporate Affairs, responsible for Communications, Public Affairs and CSR for the Group.
Vanina is the Vice-President and Head of Global Public Affairs, Sanofi Genzyme since December 2019. Vanina is responsible for Sanofi’s Public Affairs strategies for Neurology, Oncology, and Immunology, Rare Disease and Rare Blood Disorders. She is working closely with Sanofi Genzyme leadership and across Corporate Affairs to ensure patients have appropriate access to the medicines they need and to strengthen Sanofi’s leadership in Specialty Care. She is based in Cambridge, US.
Vanina has developed a solid experience as a Public Affairs strategist and advocacy leader with a demonstrated track record in bringing innovation closer to patients. A lawyer by training, Vanina has devoted her career to create shared value for patients, caregivers, health systems and the healthcare industry. Before moving to the US in 2016, Vanina honed her skills in launch preparedness, corporate affairs, strategic communications, vaccine policy and corporate social responsibility at Sanofi Pasteur in France in a global role, Merck/MSD in Belgium covering Europe and Canada and Sanofi Pasteur MSD covering Europe. Vanina started her career with the law firm Cleary Gottlieb in Brussels.
Vanina had the privilege to help advance public health while working at the global vaccine alliance Gavi as Chief of Staff then in resource mobilization and through her board tenure at CSR Europe and the trade association Vaccines Europe. She currently serves as a trade advisor for the French government.
Marie-José Quentin-Millet is currently Delegate Director-General of Sanofi Pasteur SA, Sanofi's Vaccines Division. A scientist by training, with a doctorate in Biochemistry, she was awarded a postdoctoral fellowship at the National Institute of Health in Bethesda (USA), and attended the Advanced Management Program, Wharton Business School. She has had nearly 30 years of experience in Research and Development, and has actively contributed to the development of vaccines that are marketed today, such as pediatric combination vaccines, influenza vaccines and dengue fever vaccines.
During her career, she has led large, multidisciplinary teams on several continents. Beyond science, which remains a passion, her most exciting challenges are to identify and develop talents, learn how to work together in respect of diversity, give the necessary space for everyone's skills to be expressed, and cooperate effectively. When these challenges are met, anything is possible, including the prevention and eradication of infectious diseases.
She contributes to the life sciences ecosystem in Lyon, notably through her participation on the boards of several institutions and organizations.
Medicinal Chemist in the Lead Generation to Candidate Realization Department at Vitry sur Seine - Secretary of the European Works Council.
He joined the Group in 1992 at the research center of Vitry sur Seine (Rhone Poulenc Rorer) as a Medicinal Chemist (synthesizing molecules with potential biological activities, mainly in the field of oncology), and he still holds this position.
Stéphane Galiné has also been Secretary of the Group’s European Works Council since October 2013, and a member of the CFDT trade union.
In her current position since 2012, Simone is coordinating a network of Country CSR Correspondents. She works with CSR Correspondents to define country CSR priorities and action plans based on stakeholders’ expectations and specificities of each country, in line with the group CSR approach. She also directly supports the Countries to implement CSR initiatives.
Simone is a biologist and holds a specialization in industrial microbiology. She joined the Group in 1986. Since then, she held positions in biotechnology research labs, clinical research, medical, marketing, market access and health economics at global, regional and country levels.
This experience is now used to understand public health issues in the countries where the Group operates and develop partnerships to contribute to address public health priorities.
Professor Alice Dautry is the former president of the Institut Pasteur, a private state-approved foundation dedicated to biomedical research, public health, education and training.
Alice Dautry has spent her career in both France and the USA [the National Institutes of Health (NIH) and the Massachusetts Institute of Technology (MIT) in research, research management and teaching, as Professor at the Ecole Polytechnique and Director of the Molecular Biology Cell course at the Institut Pasteur. She is the author of many scientific publications in the fields of cell biology, immunology, receptors and infectious agents.
Alice Dautry has also had many other responsibilities: advisor and evaluator for research and higher education institutions, and a member of scientific councils and boards of directors in France and Europe. She currently serves on the Board of Directors of the Ecole Polytechnique, Sanofi-Pasteur, the Chr Hansen company (Denmark), the Austrian Institute of Science and Technology (Austria), the Drugs for Neglected Diseases Initiative (Switzerland) and Pasteur Institutes around the world. She is also a member of the Leopoldina Academy and the Academy of Technology.
Alice Dautry is an officer of the French Legion of Honor and Legion of Merit.
After qualifying as a doctor in 1995 at the University Cheikh Anta Diop, Dr. Safiatou Thiam continued her training with a Master of Science at the Institute of Tropical Medicine Antwerp in 1997, a number of specialized degrees earned in Dakar and France, and a post-graduate diploma in Public Health in Developing Countries from the University of Pierre et Marie Curie (Paris VI) in 2001.
On September 13, 2007, Dr. Safiatou Thiam was appointed Minister of Health and Prevention and carried out her duties until May 2009.
As a member of the National AIDS Council (CNLS), she supports Global Fund programs that combat the AIDS pandemic.
Since 2007, she has been the coordinator of UNAIDS in Senegal in support of the management of prevention and care programs and projects covering AIDS, Tuberculosis and Malaria. She is also an international heath consultant for West African countries.
PhD, Professor International Economics Faculty of Economics and Business administration University Complutense of Madrid, Spain.
Born in Madrid in 1955, with a doctorate in international economics, he is currently Professor and Director of Development Policy Group at the Complutense University in Madrid (Spain) and has been professor at Nebrija University in Madrid and the University of Geneva, Switzerland. He is also Director of the International Department of “GNOSS Semantic System” and a strategy consultant to several governments in Africa and Latin America, as well as to international organizations in the areas of the knowledge economy, sustainable development and green competitiveness.
For over 23 years he was a permanent employee of the United Nations Conference on Trade and Development (UNCTAD) in Geneva. He is the founder of and has led the BIOTRADE initiative (competitiveness, development and biodiversity) and is now launching GRECO (Green Competitiveness In The Mediterranean) with the Regional Action Centre for Cleaner Production (CP/RAC) in Barcelona.
The leading economist for the Special Mission for Peace in Afghanistan tasked by the UN Security Council (1994-95), he has also worked at the Economic Commission for Latin America and the Caribbean (ECLAC), in Chile, and at the SELA in Caracas. He is the Director of the Research Department of the Central-Hispano Bank (now Banco Santander), Madrid and is also a member of the Commission on Globalization in the “Forum on the World Situation”. He is the author of various books and publications in his areas of expertise.
Lionel Zinsou is an economist and former Prime Minister of the Republic of Benin. (2015-2016). Born in 1954, he holds a Beninese and a French citizenship.
From 2008 to 2015, he served as Chief Executive Officer and Chairman of PAI Partners, a French private equity firm with more than € 11 billion in assets under management.
Prior to joining PAI, Mr Zinsou worked for 11 years at Rothschild & Cie, where he was General Partner from 1997. In this capacity he served as Head of Global Consumer Goods and Head of Africa Middle East until 2008.
Previously, Mr Zinsou had worked at world leading food company Danone, which he joined in 1986 as Financial Controller. He then went on to serve as its Corporate Development Director, Head of Grocery UK-USA operations, CEO of the Grocery Division and Executive Committee member.
His professional career began in public service as an academic. As a graduate from the Ecole Normale Supérieure (Agrégation in Social Sciences and Economic History – 1978) the premier French institute for higher education and research, as well as of the Institut d’Etudes Politiques (Sciences –Po) and the Paris IV and VII Universities. He worked as a Research Student at the London School of Economics. In 1978 he went on to work, first as Associate Professor and then as Lecturer in Economics and Social Sciences at the University of Paris XIII. He remained Director of the Centre for Social Sciences of the Ecole Normale Supérieure from 1983 to 1986.
During that time he also worked as a consultant to the United Nations Development Programme and the United Nations Industrial Development Organization. In addition, he was involved in two long-term missions for the French Government, first as a researcher in the “Research and Prospective” division within the Ministry of Industry (1980-1984) and then as a member of the office of Prime Minister Laurent Fabius (1983-1986).
Mr Zinsou is currently on the board of several companies including the PAI supervisory Board (Vice-chair), the Danone group Board of Directors and the Americana Board (UAE).
He is also actively involved in community work, serving as President of the Foundation de l’École Normale Supérieure, of the Foundation Terra Nova and of the Société des Amis du Musée Branly-Jacques Chirac, as well as Director of the Ashinaga Foundation (Tokyo), the Sanofi Espoir Foundation, and the Foundation Zinsou, the latter of which he also founded.